

IAP5 Rec'd PCT/PTO 01 SEP 2006

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

10/591454

In re application of

Docket No: Q96749

Ituro INOUE, et al

Appln. No.: National Stage of PCT/JP2005/003383

Confirmation No.: Unknown

Group Art Unit: Unknown

Filed: September 1, 2006

Examiner: Unknown

For: METHOD OF DETECTING CARCINOGENESIS CAUSED BY HEPATITIS B VIRUS

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

A copy of an International Search Report (PCT/JP2005/003383) in a counterpart application is submitted herewith. The USPTO should receive copies of the references cited in the International Search Report from the International Bureau. Applicant will furnish any missing references upon request.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action

10/591454

INFORMATION DISCLOSURE STATEMENT
Appln. No.: National Stage of PCT/JP2005/003383
Attorney Docket No. Q96749

on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,


Gordon Kit
Registration No. 30,764

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: September 1, 2006

Substitute for Form 1449 A & B/PTO <u>INFORMATION DISCLOSURE</u> <u>STATEMENT BY APPLICANT</u> <i>(use as many sheets as necessary)</i>				1AP5 Rec'd PCT/PTO 01 SEP 2006 <i>Appropriate if Known</i>	
				Application Number	National Stage of
				Confirmation Number	Unknown
				Filing Date	September 1, 2006
				First Named Inventor	Ituro INOUE
				Art Unit	Unknown
Examiner Name		Attorney Docket Number	Q96749		
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US			
		US			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		A. MERCHIO, ET AL., "RECURRENT CHROMOSOMAL ABNORMALITIES IN HEPATOCELLULAR CARCINOMA DETECTED BY COMPARATIVE GENOMIC HYBRIDIZATION", GENES CHROMOSOMES CANCER, 1997, VOL. 18, NO. 1, PAGES 59 TO 65	
		P.C. WANG, ET AL., "ANALYSIS OF INTEGRATED HEPATITIS B VIRUS DNA AND FLANKING CELLULAR SEQUENCE BY INVERSE POLYMERASE CHAIN REACTION", J. VIROL. METHODS, 2001, VOL. 92, NO. 1, PAGES 83 TO 90	
		D. G. HUNTSMAN, ET AL., "MLL2, THE SECOND HUMAN HOMOLOG OF THE DROSOPHILA TRITHORAX GENE, MAPS TO 19q13.1 AND IS AMPLIFIED IN SOLID TUMOR CELL LINES", ONCOGENE, 1999, VOL. 18, NO. 56, PAGES 7975-84	
		Y. Z. ZHOU, ET AL., "STRUCTURAL ANALYSIS OF A HEPATITIS B VIRUS GENOME INTEGRATED INTO CHROMOSOME 17p OF A HUMAN HEPATOCELLULAR CARCINOMA", J. VIROL, 1988, VOL. 62, NO. 11, PAGES 4224-31	
		P. PATERLINI-BRECHOT, ET AL., "HEPATITIS B VIRUS-RELATED INSERTIONAL MUTAGENESIS OCCURS FREQUENTLY IN HUMAN LIVER CANCERS AND RECURRENTLY TARGETS HUMAN TELOMERASE GENE ONCOGENE", 2003, VOL. 22, NO. 25, PAGES 3911-6	
		D. GOZUACIK, ET AL., "IDENTIFICATION OF HUMAN CANCER-RELATED GENES BY NATURALLY OCCURRING HEPATITIS B VIRUS DNA TAGGING", ONCOGENE, 2001, VOL. 20, NO. 43, PAGES 6233-40	
		P. H. RAO, ET AL., "CHROMOSOMAL AMPLIFICATIONS, 3q GAIN AND DELETIONS OF 2q33-q37 ARE THE FREQUENT GENETIC CHANGES IN CERVICAL CARCINOMA", BMC CANCER, 2004.02, VOL. 4, NO. 1, PAGE 5	
		C. J. WALKEY, ET AL., "IDENTIFICATION OF THREE NOVEL CDNAS FOR HUMAN PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE AND LOCALIZATION OF THE HUMAN GENE ON CHROMOSOME 17p11.2, BIOCHIM. BIOPHYS. ACTA, 1999, VOL. 1436, NO. 3, PAGES 405-12	
		K. T. FITZGERALD, ET AL., "MLL2: A NEW MAMMALIAN MEMBER OF THE TRX/MLL FAMILY OF GENES", GENOMICS, 1999, VOL. 59, NO. 2, PAGES 187-92	
		H. L. LIU, ET AL., "THE NOVEL ESTROGEN-RESPONSIVE B-BOX PROTEIN (EBBP) GENE IS TAMOXIFEN-REGULATED IN CELLS EXPRESSING AN ESTROGEN RECEPTOR DNA-BINDING DOMAIN MUTANT", MOL. ENDOCRINOL, 1998, VOL. 12, NO. 11, PAGES 1733-48	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.